Allison L. Zulli

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Sheila Miknyoczki, Hong Chang, Jennifer V. Grobelny et al. · Molecular Cancer Therapeutics · 2007 · 110 citations

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779

Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

Optimization of the β-Aminoester class of factor Xa inhibitors. part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity

Kevin R. Guertin, Charles J. Gardner, Scott I. Klein et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 52 citations · Full text

Thrombosis, Medicinal Chemistry, Biochemistry +10

The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity

Michael R. Myers, Natalie N. Setzer, Alfred P. Spada et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 45 citations

Medicinal Chemistry, Pharmaceutical Science, Medicine +8

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

Michael R. Myers, Wei He, Barbara Hanney et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 44 citations · Full text

Sar Exploration, Medicinal Chemistry, Medicine +10